Thierry Facon
Service des Maladies du Sang
Centre Hospitalier Universitaire (CHU)
Lille
France
Name/email consistency: high
- Frontline treatment in elderly patients with multiple myeloma. Facon, T., San Miguel, J., Mateos, M.V., Hulin, C. Semin. Hematol. (2009)
- Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Facon, T., Mary, J.Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J.L., Guillerm, G., Chaleteix, C., Dib, M., Voillat, L., Maisonneuve, H., Troncy, J., Dorvaux, V., Monconduit, M., Martin, C., Casassus, P., Jaubert, J., Jardel, H., Doyen, C., Kolb, B., Anglaret, B., Grosbois, B., Yakoub-Agha, I., Mathiot, C., Avet-Loiseau, H. Lancet (2007)
- Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation. Facon, T., Darre, S. Best. Pract. Res. Clin. Haematol (2007)
- Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Facon, T., Mary, J.Y., Pégourie, B., Attal, M., Renaud, M., Sadoun, A., Voillat, L., Dorvaux, V., Hulin, C., Lepeu, G., Harousseau, J.L., Eschard, J.P., Ferrant, A., Blanc, M., Maloisel, F., Orfeuvre, H., Rossi, J.F., Azaïs, I., Monconduit, M., Collet, P., Anglaret, B., Yakoub-Agha, I., Wetterwald, M., Eghbali, H., Vekemans, M.C., Maisonneuve, H., Troncy, J., Grosbois, B., Doyen, C., Thyss, A., Jaubert, J., Casassus, P., Thielemans, B., Bataille, R. Blood (2006)
- Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laï, J.L., Leleu, X., Jouet, J.P., Bauters, F., Harousseau, J.L., Bataille, R., Mary, J.Y. Blood (2001)